title: [High-dose polychemotherapy of patients with poor-prognosis anaplastic T.0-large cell ALK+ lymphosarcoma].
abstract: OBJECTIVE
  To evaluate efficacy of the protocol NHL BFM-90 in the treatment of adult anaplastic large cell lymphosarcoma (ALCL) ALK+ and validity of addition of transplantation of autologous stem hemopoietic cells (ASHC) into first line treatment.
  
  
  METHODS
  We treated 13 patients with stage III-IV ALCL ALK+. The age of the patients ranged from 17 to 44 years (median 26 years). The diagnosis was made using morphological, histological, immunohistochemical methods with application of monoclonal antibodies to CD30, ALK, CD3, CD4, CD8, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA. The patients were treated according to the protocol NHL BFM-90. ASHC was made in two patients with the disease stage IV.
  
  
  RESULTS
  We obtained a complete remission in 12 of 13 patients, one woman died of infectious complications in the beginning of the treatment, one man had early recurrence 45 days after the end of the treatment with lethal outcome and disease progression. Two patients at stage IV and poor prognosis had undergone ASHC transplantation. They are now in remission for 5 and 12 months.
  
  
  CONCLUSIONS
  ALCL ALK+ is characterized by an aggressive clinical course (11 of 13 patients had stage III-IV), high rate of extranodal lesions. Twelve patients achieved a complete remission, 11 (91.6%) of 12 patients are alive in observation median 27 months. We effectively used ASHC transplantation in the first-line treatment of 2 patients with stage IV of the disease and poor prognosis.
authors.forename: L G
authors.initials: LG
authors.lastname: Aitova
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Vinogradova
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: I N
authors.initials: IN
authors.lastname: Lutsenko
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: K S
authors.initials: KS
authors.lastname: Momotiuk
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: A I
authors.initials: AI
authors.lastname: Vorob'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases; D012074:Remission Induction; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D055815:Young Adult
chemical_list: C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases